Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bausch + Lomb Corporation Common Shares
(NY:
BLCO
)
15.23
+0.04 (+0.26%)
Official Closing Price
Updated: 4:10 PM EDT, Sep 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bausch + Lomb Corporation Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
September 11, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
September 09, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
Earnings Scheduled For July 30, 2025
July 30, 2025
Via
Benzinga
Examining the Future: Bausch & Lomb's Earnings Outlook
July 29, 2025
Via
Benzinga
Bausch + Lomb (BLCO) Stock Trades Up, Here Is Why
September 08, 2025
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.9% in the afternoon session after the company announced the U.S. launch of its ASANA gas permeable (GP) lenses. This new product line offers...
Via
StockStory
Topics
Economy
Initial Public Offering
Stocks
Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States
September 08, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
3 Healthcare Stocks Walking a Fine Line
September 05, 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...
Via
StockStory
Topics
Stocks
Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know
August 22, 2025
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 3.1% in the afternoon session after comments from Federal Reserve Chair Jerome Powell raised investor hopes for future interest rate cuts. The...
Via
StockStory
Topics
Economy
Initial Public Offering
Stocks
Purple, Bausch + Lomb, Etsy, Intel, and Camping World Shares Are Falling, What You Need To Know
August 21, 2025
A number of stocks fell in the afternoon session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell. The move came as U.S....
Via
StockStory
Topics
Economy
Stocks
Medical Devices & Supplies - Specialty Stocks Q2 Highlights: Bausch + Lomb (NYSE:BLCO)
August 20, 2025
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Bausch + Lomb...
Via
StockStory
Bausch + Lomb Announces Board Changes
August 18, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
1 Safe-and-Steady Stock with Competitive Advantages and 2 That Underwhelm
August 15, 2025
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via
StockStory
Bausch + Lomb to Participate in Upcoming Investor Conferences
August 14, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know
August 13, 2025
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...
Via
StockStory
Topics
Economy
Lawsuit
BLCO Q2 Deep Dive: Product Launches Offset Margin Pressures, Management Highlights Pipeline Investments
August 12, 2025
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance of $5.1 billion...
Via
StockStory
1 Stock Under $50 to Target This Week and 2 We Ignore
August 07, 2025
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...
Via
StockStory
3 Small-Cap Stocks with Warning Signs
August 06, 2025
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
Bausch Lomb (BLCO) Q2 Revenue Rises 5%
July 30, 2025
Via
The Motley Fool
Why Bausch + Lomb (BLCO) Stock Is Down Today
July 30, 2025
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.1% in the morning session after the company reported mixed second-quarter 2025 financial results where a decline in profitability overshadowed...
Via
StockStory
Topics
Artificial Intelligence
Initial Public Offering
Bausch + Lomb’s (NYSE:BLCO) Q2 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations
July 30, 2025
Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance...
Via
StockStory
Bausch + Lomb Announces Second-Quarter 2025 Results
July 30, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
July 29, 2025
Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials.
Via
Benzinga
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
July 29, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch + Lomb (BLCO) Q2 Earnings Report Preview: What To Look For
July 28, 2025
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
July 22, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Medical Devices & Supplies - Specialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers
July 20, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and its peers.
Via
StockStory
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie
July 18, 2025
This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.
Via
Benzinga
Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye
July 01, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
June 30, 2025
From
Bausch + Lomb Corporation
Via
Business Wire
BAUSCH & LOMB ALERT: Bragar Eagel & Squire, P.C. is Investigating Bausch + Lomb Corporation on Behalf of Bausch & Lomb Stockholders and Encourages Investors to Contact the Firm
June 26, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.